Browse > Article
http://dx.doi.org/10.14407/jrp.2014.39.4.168

USEFULNESS OF SIMPLE SHIELDING TECHNIQUE USING MULTILEAF COLLIMATOR IN BREAST RADIATION THERAPY  

Lee, Kyu Chan (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Lee, Seok Ho (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Lee, Seung Heon (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Sung, Kihoon (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Ahn, So Hyun (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Choi, Jinho (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Dong, Kap Sang (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Kim, Hyo Jin (Department of Radiation Oncology, Gil Medical Center, School of Medicine, Gachon University)
Chun, Yong Seon (Department of Surgery, Gil Medical Center, School of Medicine, Gachon University)
Park, Heung Kyu (Department of Surgery, Gil Medical Center, School of Medicine, Gachon University)
Publication Information
Journal of Radiation Protection and Research / v.39, no.4, 2014 , pp. 168-175 More about this Journal
Abstract
This study was designed to assess whether the conventional tangential technique, using a multileaf collimator (MLC), allows a reduced dose to the organs at risk (OAR) in breast radiation therapy. A total of forty right and left 20 for each breast cancer patients that underwent radiation therapy after breast conserving surgery were included in this study. For each patient, the planning target volume (PTV) and OAR (heart, left anterior descending artery (LAD), liver and lung) were defined and dose distribution were produced for conventional tangential beams using 6 MV photons. The treatment plans were made using the following two techniques for all patients. For the first plan (P1), MLC was designed to shield as much of OAR as possible without compromising the coverage of PTV. In the second plan (P2), the treatment plan was created without using MLC. Dose-volume histograms for OARs were calculated for all plans. For left breast cancer, the percentage of maximum dose ($D_{max%}$) and mean dose ($D_{mean%}$) of OARs (heart and LAD) were calculated, and for right breast cancer, the percentage of the mean dose ($D_{mean%}$) of the liver was calculated. The $D_{mean%}$ of the lung was calculated in all patients. The mean values of $D_{max%}$ of the heart ($86.9{\pm}19.5%$ range, 35.1-100.6%) in P1 were significantly lower than in P2 ($98.3{\pm}3.4%$ range, 91.7-105.2%) (p=0.001). The mean values of $D_{max%}$ of LAD ($78.4{\pm}22.5%$ range, 26.5-99.7%) in P1 was significantly lower than in P2 ($93.3{\pm}8.1%$ range, 67.9-102.1%) (p<0.001). In P1, the mean values of $D_{mean%}$ of the liver ($4.8{\pm}2.0%$) were significantly lower than in P2 ($6.2{\pm}2.5%$) (p<0.001). The mean values of $D_{mean%}$ of the lung were significantly lower in P1 ($9.3{\pm}2.3%$) than in P2 ($9.7{\pm}2.4%$) (p<0.001). P1, by using MLC, allows a significantly reduced dose to OAR compared with P2. We can suggest that it is reasonable to routinely use MLC in the conventional tangential technique for breast radiation therapy considering the primary tumor location.
Keywords
Breast cancer; Multileaf collimator; Organs at risk;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716.   DOI   ScienceOn
2 Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New. Engl. J. Med. 2002;347(16):1227-1232.   DOI   ScienceOn
3 Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557-565.   DOI   ScienceOn
4 Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366(9503):2087-2106.   DOI   ScienceOn
5 Darby SC, Ewertz M, McGale P, et al. Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. New. Engl. J. Med. 2013;368(11):987-998.   DOI   ScienceOn
6 Taylor CW, Povall JM, McGale P, et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int. J. Radiat. Oncol. Biol. Phys. 2008;72(2):501-507   DOI   ScienceOn
7 Aznar MC, Korreman S-S, Pedersen AN, et al. Evaluation of dose to cardiac structures during breast irradiation. Br. J. Radiol. 2011;84(1004): 743-746.   DOI   ScienceOn
8 Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int. J. Radiat. Oncol. Biol. Phys. 2005;61(3):842-850.   DOI   ScienceOn
9 Shimizu Y, Kodama K, Nishi N, et al. Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950-2003. BMJ. 2010;340:5349.   DOI   ScienceOn
10 Taylor CW, Povall JM, McGale P, et al. Cardiac Dosefrom tangential breast cancer radiotherapy in the year 2006. Int. J. Radiat. Oncol. Biol. Phys. 2008;72(2):501-507.   DOI   ScienceOn
11 Bartlett FR, Yarnold JR, Donovan EM, Evans PM, Locke I, Kirby AM. Multileaf collimation cardiac shielding in breast radiotherapy: Cardiac doses are reduced, but at what cost? Clin. Oncol. 2013;25(12):690-696.   DOI   ScienceOn
12 Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011;79(1):10-18.   DOI   ScienceOn
13 Bartelink H, Garavaglia G, Johansson KA, et al. Quality assurance in conservative treatment of early breast cancer. Report on a consensus meeting of the EORTC Radiotherapy and Breast Cancer Cooperative Groups and the EUSOMA (European Society of Mastology). Radiother. Oncol. 1991;22(4):323-326.   DOI   ScienceOn
14 ICRU. Prescribing, recording and reporting photon beam therapy. ICRU Report 62. 1999.
15 Allen AM, Czerminska M, Jänne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2006;65(3):640-645.   DOI   ScienceOn
16 Darby SC, McGale P, Taylor CW, et al. Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557-565.   DOI   ScienceOn
17 Stevens CW, Forster KM, Smythe WR, et al. Radiotherapy for mesothelioma. Hematol. Oncol. Clin. North Am. 2005; 19(6):1099-1115.   DOI   ScienceOn
18 Yorke ED, Jackson A, Rosenzweig KE, et al. Correlation of dosimetric factors and radiation pneumonitis for non-small- cell lung cancer patients in a recently completed dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 2005; 63(3):672-682.   DOI   ScienceOn
19 Zhang X-J, Sun J-G, Sun J, et al. Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J. Cancer Res. Clin. Oncol. 2012;138(12):2103-2116   DOI   ScienceOn
20 Cheng JCH, Wu JK, Huang CM, et al. Radiationinduced liver disease after radiotherapy for hepatocellular carcinoma: Clinical manifestation and dosimetric description. Radiother. Oncol. 2002; 63(1):41-45.   DOI   ScienceOn
21 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin. Liver Dis. 2013; 17(3):375-397.   DOI   ScienceOn
22 McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother. Oncol. 2011;100(2):167-175.   DOI   ScienceOn
23 Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int. J. Radiat. Oncol. Biol. Phys. 1990;19(4):833-842.   DOI   ScienceOn
24 Kontos M, Allen DS, Agbaje OF, et al. Factors influencing loco-regional relapse in older breast cancer patients treated with tumour resection and tamoxifen. Eur. J. Surg. Oncol. 2011;37(12):1051-1058.   DOI   ScienceOn
25 Price P, Walsh G, McKinna AJ, et al. Patterns of breast relapse after local excision +/- radiotherapy for early stage breast cancer. Radiother. Oncol. 1988;13(1):53-60.   DOI   ScienceOn
26 Horst KC, Smitt MC, Goffinet DR, et al. Predictors of local recurrence after breast-conservation therapy. Clin. Breast Cancer. 2005;5(6):425-438.   DOI   ScienceOn
27 Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. J. Clin. Oncol. 2009;27(30):4939-47.   DOI   ScienceOn